Simultaneously, the results of the real-world study were consistent with clinical trials, proving that pyrotinib is beneficial for HER2-positive metastatic BC patients by maintaining an excellent clinical benefit rate of 87.5% [28]. This evidence concerns the gene ERBB2 and breast cancer.